Loading clinical trials...
Loading clinical trials...
Phase 1b Clinical Study to Investigate the Safety and Immunogenicity of the Bris10 (A/Brisbane/10/2007) M2SR and Sing2016 (A/Singapore/INFIMH-16-0019/2016) M2SR H3N2 Monovalent Influenza Vaccines
Conditions
Interventions
LD Sing2016 M2SR H3N2 influenza vaccine
MD Sing2016 M2SR H3N2 influenza vaccine
+3 more
Locations
4
United States
RCA
Hollywood, Florida, United States
JCCT
Lenexa, Kansas, United States
AMR Lexington
Lexington, Kentucky, United States
AMR Norfolk
Norfolk, Virginia, United States
Start Date
September 3, 2019
Primary Completion Date
July 1, 2020
Completion Date
July 1, 2020
Last Updated
March 4, 2022
NCT06672692
NCT07128615
NCT04896853
NCT06622590
NCT07430410
NCT05202379
Lead Sponsor
FluGen Inc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions